Clinical handbook of psychotropic drugs
Author(s)
Bibliographic Information
Clinical handbook of psychotropic drugs
Hogrefe & Huber Publishers, c2001
11th rev. ed. / contributions from Roger S. McIntyre ... [et al.]
Available at / 2 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references (p. 221-224) and index
Description and Table of Contents
Description
A handbook of psychotropic drugs. It is divided into logical main sections based on area of application. For each category of drug it details: therapeutic effects; pharmacology, pharmacokinetics and dosing; onset and duration of action; adverse effects, indications, contraindications, and precautions; toxicity; drug interactions; use in the young, old and pregnant; nursing implications; and patient instructions. A comprehensive index of drug names and tables are included to enhance the speed and accuracy with which the reader can find the relevant information. This eleventh edition includes new sections on anticonvulsants, classified into first- and second-generation drugs, as well as all the latest drugs, such as Lamotrigine and Topiramate (anticonvulsants), Rivastigmine (cognition enhancer), and Omega-3 fatty acids (herbal preparations). All drugs are commonly referred to by generic names, as well as by commonly-used trade names, and there are patient information sheets with important advice to be handed out to patients.
Table of Contents
- Part 1 Antidepressants: selective serotonin-reuptake inhibitors (SSRI)
- norepinephrine dopamine-reuptake inhibitor (NDRI)
- selective serotonin norepinephrine reuptake inhibitor (SNRI)
- serotonin-1 antagonists/reuptake inhibitors (SARI)
- noradrenergic/specific serotonergic agent (NaSSA)
- non-selective cyclic antidepressants
- effects of antidepressants on neurotransmitters/receptors
- pharmacological effects of antidepressants on neurotransmitters/receptors
- frequency of adverse reactions to cyclic antidepressants at therapeutic doses
- reversible inhibitor of MOA-A (RIMA)
- irreversible monoamine oxidase inhibitors
- frequency of adverse reactions to MAOI antidepressants at therapeutic doses
- antidepressant doses
- switching antidepressants
- antidepressant augmentation strategies. Part 2 Electroconvulsive therapy (ECT). Part 3 Antipsychotics (neuroleptics): "novel" antipsychotics (neuroleptics)
- "conventional" antipsychotics (neuroleptics)
- antipsychotic doses
- effects of antipsychotics on neurotransmitters/receptors
- pharamcological effects of antipsychotics on neurotransmitters/receptors
- frequency of adverse reactions to antipsychotics at therapeutic doses
- antipsychotic doses
- comparison of depot antipsychotics
- extrapyramidal side effects of antipsychotics
- switching antipsychotics
- antipsychotic augmentation strategies. Part 4 Antiparkinsonian agents: effects on extrapyramidal symptoms
- comparison of antiparkinsonian agents. Part 5 Anxiolytic agents: benzodiazepines
- comparison of the benzodiazepines
- buspirone. Part 6 Hypnotics/sedatives: comparison of hypnotics/sedatives. Part 7 Mood stabilizers: lithium
- anticonvulsants
- l-tryptophan. Part 8 Psychostimulants: comparison of the psychostimulants. Part 9 Cognition enhancers: comparison of atecylcholinesterase inhibitors. Part 10 Sex-drive depressants: comparison of sex-drive depressants. Part 11 Drugs of abuse: alcohol
- hallucinogens
- stimulants
- opiates/narcotics
- inhalants/aerosols
- gamma hydroxy butyrate (GHB)
- flunitrazepam. Part 12 Treatment of substance use disorders: disulfiram
- naltrexone
- methadone. Part 13 New unapproved treatments of psychiatric disorders: adrenergic agents
- calcium channel blockers
- cholinergic agents
- dopaminergic agents
- GABA-agents/anticonvulsants
- peptides
- serotonergic agents
- serotonin antagonists
- steroid biosynthesis inhibitors
- miscellaneous. Part 14 Herbal (natural) products.
by "Nielsen BookData"